Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
9
NCT01858181
Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 31, 2015
Completion: Not specified